KESTRA MED TECHNOLOGIES LTD SEC Filings

KMTS NASDAQ

Welcome to our dedicated page for KESTRA MED TECHNOLOGIES SEC filings (Ticker: KMTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Clinical-trial milestones, FDA clearance updates, and capital needs make Kestra Medical Technologies’ disclosures unusually dense. Investors who search “Kestra Medical Technologies insider trading Form 4 transactions” or try to mine a 200-page prospectus know the challenge of locating critical details on the ASSURE WCD and broader Cardiac Recovery System platform.

Stock Titan’s AI converts complexity into clarity. Our engine provides understanding Kestra Medical Technologies SEC documents with AI, delivering real-time alerts the moment a Kestra Medical Technologies Form 4 insider transactions real-time notice posts to EDGAR. Looking for the latest Kestra Medical Technologies quarterly earnings report 10-Q filing? We highlight revenue, R&D spend, and device adoption in minutes. Each Kestra Medical Technologies 8-K material events explained entry is tagged so you can assess FDA submissions or partnership news without wading through legal prose.

The platform also surfaces the Kestra Medical Technologies annual report 10-K simplified, breaking down clinical evidence, manufacturing capacity, and cash runway. Dashboards merge Kestra Medical Technologies earnings report filing analysis with executive pay figures from the Kestra Medical Technologies proxy statement executive compensation sections. Need trading context? Track every Kestra Medical Technologies executive stock transactions Form 4 to gauge insider sentiment. With AI-powered summaries, expert commentary, and comprehensive coverage of all filing types, you move from raw disclosure to confident decisions—no medical-device jargon required.

07/15/2025 04:12 PM

Filing

[8-K] Kestra Medical Technologies, Ltd. Reports Material Event

Rhea-AI Summary

Amaze Holdings, Inc. (NYSE American: AMZE), formerly Fresh Vine Wine, filed an 8-K dated 11 July 2025 to disclose a new consulting agreement and related unregistered share issuance.

Consulting Agreement: Signed 11 July 2025 with DNA Holdings Venture Inc. (Puerto Rico) for a 12-month term, auto-renewable for another 12 months unless cancelled on 30-days notice.
Scope of Services: Crypto strategy & token architecture, e-commerce/Web3 integration, cross-border currency solutions, credibility/visibility support and market-making for the Company’s planned Token Generation Event.
Consideration: Company issued 100,000 common shares to the Consultant. No cash payment disclosed.
Unregistered Securities: Shares issued under Section 4(a)(2) and/or Rule 506(b) of Regulation D, relying on the private-offering exemption.
Reg FD: A press release announcing the agreement was furnished as Exhibit 99.1 on 15 July 2025.
Exhibits: 10.1 (Consulting Agreement), 99.1 (Press Release), 104 (Cover Page iXBRL file).

No financial performance metrics were provided in this filing. The transaction introduces crypto-related strategic initiatives while creating modest share dilution.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

5.57%

FAQ

What is the current stock price of KESTRA MED TECHNOLOGIES (KMTS)?

The current stock price of KESTRA MED TECHNOLOGIES (KMTS) is $15.9 as of July 18, 2025.

What is the market cap of KESTRA MED TECHNOLOGIES (KMTS)?

The market cap of KESTRA MED TECHNOLOGIES (KMTS) is approximately 780.0M.

What is the primary focus of Kestra Medical Technologies Ltd?

The company specializes in developing wearable medical devices and digital healthcare solutions aimed at improving patient outcomes in cardiovascular disease management.

What is encompassed within the Cardiac Recovery System platform?

The platform integrates continuous cardiac monitoring, therapeutic intervention, digital health management, and patient support services, with the ASSURE WCD as a central component.

How does Kestra Medical Technologies generate revenue?

Revenue is primarily generated through the sale of wearable devices, subscription-based digital healthcare services, and associated aftercare support offerings.

What sets Kestra Medical Technologies apart from its competitors?

Its integrated approach, which combines advanced monitoring, real-time therapeutic intervention, and comprehensive digital health support, differentiates it in the competitive landscape of medical device technology.

How does the ASSURE WCD contribute to patient safety?

The ASSURE WCD continuously monitors cardiac rhythms and employs intelligent algorithms to detect irregularities, ensuring prompt therapeutic responses to reduce the risk of sudden cardiac arrest.

What role do digital health solutions play in the company’s operations?

Digital health solutions enable remote patient monitoring, facilitate streamlined communication between patients and healthcare professionals, and enhance overall device functionality and patient care management.

How is regulatory compliance ensured for the company’s products?

Kestra Medical Technologies follows rigorous quality assurance protocols, comprehensive testing procedures, and strict adherence to regulatory standards to ensure the safety and efficacy of its solutions.